AstraZeneca has revealed the proposed designs for its new global R&D centre and corporate headquarters in Cambridge in the UK. The unveiling of the plans for an ambitious, purpose built ...
Dealbreaker on MSN18d
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec AcquisitionUnder acquisition terms announced Monday, AstraZeneca will pay $425 million up front for all outstanding equity of privately ...
The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...
Cambridge-headquartered AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R & D centre ...
(Alliance News) - AstraZeneca PLC on Monday detailed progress with two of its drugs as it reported an endorsement in the EU and an approval in the US.
The minister for science, Sir Patrick Vallance, was in Cambridge last week for the unveiling of the first-ever advisory ...
News Medical on MSN11d
ELRIG announces Prof Rory Johnson and Dr Shalini Andersson as Keynote Speakers at Therapeutic Oligonucleotides 2025ELRIG meeting on Therapeutic Oligonucleotides brings together esteemed scientists from academia, industry, and other members ...
Cambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback